Phase 3 Gene Therapy for Painful Diabetic Neuropathy
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Sponsor: Helixmith Co., Ltd.
Listed as NCT02427464, this PHASE3 trial focuses on Diabetic Neuropathy, Painful and Painful Diabetic Neuropathy and remains completed. Sponsored by Helixmith Co., Ltd., it has been updated 17 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE3
-
Mar 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 12 earlier versions
-
Jul 2022 — Sep 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2022 [monthly]
Completed PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Jul 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Helixmith Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .